

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery ID1149

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Shionogi (lusutrombopag) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Addiction • Addaction • Addiction Today • ADFAM • Alcohol Concern • British Liver Trust • Compass UK • Haemophilia Society • Hepatitis B Foundation UK • ITP Support Association • Lifeline Project • Liver4Life • Muslim Council of Great Britain • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Turning Point <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Surgeons of Great Britain and Ireland • British Association for the Study of the Liver • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatric Society • British Infection Association • British Society for Haematology • British Viral Hepatitis Group • Hepatitis Nurse Specialist Forum 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Cochrane Infectious Diseases group • Foundation for Liver Research • MRC Clinical Trials Unit • National Institute for Health Research • UK National Screening Committee <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

Provisional matrix for the technology appraisal of lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery ID1149

Issue date: January 2018

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Haemophilia Nurses Association • NHS Blood and Transplant • Positive Prevention Plus • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • UK Clinical Virology Network • UK Forum on Haemoglobin Disorders • UK Harm Reduction Alliance • UK Haemophilia Centre Doctors' Organisation • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Chiltern CCG • NHS Portsmouth CCG • Welsh Government 	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.